Chemically programmable immunity

• US 8,263,082 B2
• Filed: 01/11/2010
• Issued: 09/11/2012
• Est. Priority Date: 12/22/1999
• Status: Expired due to Term

• Current Assignee: Centauri Therapeutics Limited
• Original Assignee: Altermune Technologies, LLC
• Inventors: Mullis, Kary
• Primary Examiner(s): Saunders, David A
• Application Number:
  US12/685,257
• Publication Number:
  US 20100247535A1
• Time in Patent Office: 974 Days
• Field of Search: None
• US Class Current: 424/178.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/541 Mucosal route
• CPC Class Codes: A61K 2039/6025 Nucleotides
• CPC Class Codes: A61K 2039/627 characterised by the linker
• CPC Class Codes: A61K 39/07 Bacillus
• CPC Class Codes: A61K 39/385 Haptens or antigens, bound to carriers
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C07K 16/1242 from Pasteurellaceae (F), e.g. Haemophilus influenza
• CPC Class Codes: C07K 2317/55 Fab or Fab'
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Methods and compositions for immediately immunizing an individual against any molecule or compound. The present invention comprises an immunity linker with at least two sites; (1) at least one first binding site that binds to an immune response component in an individual that has been pre-immunized with a universal immunogen, and (2) at least one second binding site that binds specifically to a desired compound or molecule, the target.

Claims

1. A method of increasing a humoral immune response to a target in an individual comprising,

administering to the individual an effective amount of a composition comprising one or more immunity linkers,

wherein the linkers comprise at least one first binding site and at least one second binding site,

wherein the first binding site binds to any humoral immune response component of a pre-existing immune response,

wherein the second binding site binds to the target, and

wherein the target normally elicits a cellular immune response in the individual.

2. The method of claim 1, wherein the target is a cancer cell or viral infected cell.

3. The method of claim 1, wherein the target is a cancer cell.

4. The method of claim 1, wherein the at least once second binding site is an aptamer nucleic acid.

5. The method of claim 1, wherein the one or more immunity linkers comprise, two or more first binding sites that differ in

a) specificity for different sub-structures on the immune response component, or

b) affinity for the same sub-structures on the immune response component.

6. The method of claim 1, wherein the at least one second binding site comprises an antibody or a fragment thereof.

7. The method of claim 1, wherein the one or more immunity linkers comprise two or more second binding site that differ in

a) specificity for different epitopes on the target, or

b) affinity for the same epitope on the target.

8. A method of tuning or tailoring a humoral or innate immune response to a target in an individual comprising,

administering to the individual an effective amount of a composition comprising one or more immunity linkers,

wherein the linkers comprise at least one first binding site that binds to any humoral or innate immune response component of a pre-existing immune response,

further comprising at least one second binding site that binds to the target, and wherein the target normally elicits a cellular immune response in the individual.

9. The method of claim 8, wherein the target is a pathogen.

10. The method of claim 8, wherein the target is an altered cell.

11. The method of claim 10, wherein the altered cell is a cancer or viral infected cell.

12. The method of claim 8, wherein the at least one second binding site comprises an aptamer nucleic acid.

13. The method of claim 8, wherein the at least one second binding site comprises an antibody or a fragment thereof.

14. The method of claim 8, wherein the one or more immunity linkers comprise two or more first binding site that differ in

a) specificity for different sub-structures on the immune response component, or

b) affinity for the same sub-structures on the immune response component.

15. The method of claim 14, wherein the immune response component comprises an antibody.

16. The method of claim 8, wherein the one or more immunity linkers comprise two or more second binding site that differ in

a) specificity for different epitopes on the target, or

b) affinity for the same epitope on the target.